Werewolf Therapeutics (HOWL) Price & Analysis

Compare

663 Followers

HOWL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.60 - $4.18

Previous CloseN/A

Volume113.58K

Average Volume (3M)547.95K

Market Cap

$53.40M

Enterprise Value-$55.46M

Total Cash (Recent Filing)$92.93M

Total Debt (Recent Filing)$10.43M

Price to Earnings (P/E)―

Beta1.58

Next Earnings

Aug 07, 2025

EPS Estimate

-0.47

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding44,873,646

10 Day Avg. Volume329,562

30 Day Avg. Volume547,953

Financial Highlights & Ratios

PEG Ratio0.70

Price to Book (P/B)0.48

Price to Sales (P/S)0.00

P/FCF Ratio-1.34

Enterprise Value/Market Cap-1.04

Enterprise Value/Revenue-3.53

Enterprise Value/Gross Profit-80.49

Enterprise Value/Ebitda0.25

Forecast

1Y Price Target

$8.20

Price Target Upside589.08% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Werewolf Therapeutics News

PremiumCompany Announcements

Werewolf Therapeutics Adopts New Bylaws and Elects Directors

1M ago

HOWL

PremiumThe Fly

Werewolf Therapeutics price target lowered to $9 from $10 at BofA

2M ago

HOWL

PremiumCompany Announcements

Werewolf Therapeutics Receives Nasdaq Deficiency Notice

2M ago

HOWL

PremiumRatings

Strategic Expansion and Clinical Potential of Werewolf Therapeutics’ PREDATOR Platform Boosts Buy Rating

2M ago

HOWL

PremiumThe Fly

Werewolf Therapeutics price target lowered to $6 from $8 at Wedbush

2M ago

HOWL

PremiumCompany Announcements

Werewolf Therapeutics Reports Q1 2025 Financial Results

2M ago

HOWL

PremiumThe Fly

Werewolf Therapeutics files $150M mixed securities shelf

2M ago

HOWL

PremiumThe Fly

Werewolf Therapeutics reports Q1 EPS (40c), consensus (43c)

2M ago

HOWL

See All HOWL News

See All News >

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe company ended the quarter with approximately $122.8 million in cash, expected to fund operations until 2Q26, indicating strong financial stability.

Investment OpportunityWerewolf represents an interesting investment opportunity with a partnership with Jazz Pharmaceuticals and a cash position of $122.8MM.

Strategic ExpansionWerewolf's strategic expansion of their PREDATOR masking platform to CD3 T-cell engagers is supported by robust clinical validation and industry interest.

Bears Say

Clinical UncertaintyThere is uncertainty whether the outcomes of WTX-124’s monotherapy and combination trials will be robust enough to engage an investor base generally disinterested in novel cytokine programs.

Revenue PerformanceWerewolf reported no revenues for 4Q24 as expected, and R&D expenses were higher than estimated.

Strategic DirectionIt is unlikely that the new strategic direction with TCE platform will result in significant appreciation for HOWL in the near-term due to its nascent development stage.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

27.83%

Insiders

5.22% Mutual Funds

42.46% Other Institutional Investors

18.71% Public Companies and Individual Investors

Detailed Ownership Overview >

HOWL FAQ

What was Werewolf Therapeutics’s price range in the past 12 months?

Werewolf Therapeutics lowest stock price was $0.59 and its highest was $4.18 in the past 12 months.

What is Werewolf Therapeutics’s market cap?

Werewolf Therapeutics’s market cap is $53.40M.

When is Werewolf Therapeutics’s upcoming earnings report date?

Werewolf Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is in 23 days.

How were Werewolf Therapeutics’s earnings last quarter?

Currently, no data Available

Is Werewolf Therapeutics overvalued?

According to Wall Street analysts Werewolf Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Werewolf Therapeutics pay dividends?

Werewolf Therapeutics does not currently pay dividends.

What is Werewolf Therapeutics’s EPS estimate?

Werewolf Therapeutics’s EPS estimate is -0.47.

How many shares outstanding does Werewolf Therapeutics have?

Werewolf Therapeutics has 44,873,646 shares outstanding.

What happened to Werewolf Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Werewolf Therapeutics?

Currently, no hedge funds are holding shares in HOWL

Werewolf Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-82.81%

Trailing 12-Months

Asset Growth

-39.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Werewolf Therapeutics

Werewolf Therapeutics, Inc. (HOWL) is a biopharmaceutical company focused on developing transformative cancer immunotherapies. The company operates in the biotechnology sector, specializing in the discovery, development, and commercialization of innovative therapeutics designed to harness the body's immune system to fight cancer. Werewolf's core products include a proprietary class of proinflammatory molecules called 'INDUKINE' molecules, which are engineered to stimulate the immune system selectively within the tumor microenvironment, aiming to improve efficacy and minimize systemic toxicity.

HOWL Stock 12 Month Forecast

Average Price Target

$8.20

▲(589.08%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","13":"$13","-1":"-$1","2.5":"$2.5","9.5":"$9.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.5,6,9.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.2,2.0307692307692307,2.8615384615384616,3.6923076923076925,4.523076923076923,5.353846153846154,6.184615384615385,7.015384615384616,7.846153846153847,8.676923076923076,9.507692307692308,10.338461538461539,11.169230769230769,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.2,1.7384615384615385,2.276923076923077,2.815384615384615,3.3538461538461535,3.892307692307692,4.430769230769231,4.969230769230769,5.507692307692308,6.046153846153846,6.584615384615384,7.123076923076923,7.661538461538462,{"y":8.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.2,1.4153846153846152,1.6307692307692307,1.846153846153846,2.0615384615384613,2.276923076923077,2.4923076923076923,2.707692307692308,2.923076923076923,3.138461538461538,3.3538461538461535,3.569230769230769,3.7846153846153845,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.38,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.02,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.17,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >